Morgan Stanley upgraded Acadia Pharmaceuticals to Overweight from Equal Weight with a price target of $40, up from $31. The firm believes the Daybue launch is likely to remain strong and is encouraged by the market opportunity. The firm thinks the company will be able to identify more patients and continue to grow the Rett syndrome diagnosed population, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACAD:
- Biotech Alert: Searches spiking for these stocks today
- Foot Locker upgraded, Deckers downgraded: Wall Street’s top analyst calls
- Acadia Pharmaceuticals just downgraded at Deutsche Bank, here’s why
- Acadia Pharmaceuticals announces District Court ruling in its favor
- Acadia announces favorable ruling in NUPLAZID patent litigation